This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Early Winners & Losers

StarTek (SRT - Get Report) fell after the Denver-based staffing-services company said fourth-quarter earnings will probably range between $1 million and $1.3 million, or 7 cents to 9 cents a share -- less than a third of year-ago income, which had totaled $4.4 million, or 30 cents a share. Revenue is expected at $59 million, up slightly from a year ago but falling about $5.8 million short of the Street projection. StarTek says the disappointing profits stem from lower gross margins that, at about 14%, represent a 7.6-point decline from last year. Shares were receding $2.49, or 19.5%, to $10.25.

Coley Pharmaceutical (COLY) slumped on news that the company will halt developing its hepatitis C drug candidate, Actilon, after a midphase study yielded unpromising results. The Wellesley, Mass., company will now focus on developing drugs that stimulate certain toll-like receptors (naturally occurring proteins that play a part in the immune system) for a product line called TLR Therapeutics. Shares were losing $1.14, or 11.5%, to $8.75.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MSPD $0.00 0.00%
CVS $89.68 -3.70%
NVAX $4.66 -3.20%
NBIX $32.50 -9.70%
SRT $3.77 -5.40%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs